Mr. Gilles Gagnon reports

CEAPRO ANNOUNCES RESULTS OF 2023 SHAREHOLDERS' MEETING

All proposed directors were elected to serve for a one-year term at Ceapro Inc.'s annual general and special meeting of shareholders held on June 6, 2023 (see an attached table).

Glenn Rourke, who provided 15 years of dedicated service as a director of the company, advised on June 5, 2023, that he was no longer standing for re-election. Therefore, his name was removed from the slate.

All other matters at the meeting, namely the appointment of an auditor and the approval and ratification of an amended and restated stock option plan, as proposed in the company's information circular dated April 19, 2023, were also approved by shareholders.

About Ceapro Inc.

Ceapro is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutic products for both humans and animals. The company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.